Yuhan Corporation's YH42946 Initiates Global Phase 1/2 Trial for HER2 and EGFR Mutant Cancers
Global Clinical Trial Initiation and Design
Yuhan Corporation (000100.KS) is enrolling patients in the global Phase 1/2 clinical trial (NCT06616766) of its oral tyrosine kinase inhibitor (TKI), YH42946. Registered under the development code YH42946 and its previous name, JIN-A04, this is the first human-targeted (FIH) candidate. It selectively inhibits HER2 and EGFR exon 20 insertion mutations. The trial commenced on October 2, 2024, and is being conducted at multiple sites in the United States and South Korea, with an anticipated enrollment of 161 patients. The study is structured with a dose-escalation phase to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD), followed by an expansion cohort to evaluate the objective response rate (ORR) and recommended dose.
Target and Preclinical Rationale
YH42946 targets locally advanced or metastatic solid tumors with HER2 overexpression, amplification, or mutation, and EGFR exon 20 insertion. A 2026 publication in npj Precision Oncology showed that in EGFR exon 20 insertion cell models, the IC50 was less than 10-15 nanomolars for key mutations, less than 10 nanomolars in HER2 mutant models, and greater than 1,000 nanomolars in wild-type EGFR. This selectivity is designed to reduce the skin and gastrointestinal toxicities that have limited the dose of existing pan-EGFR inhibitors while increasing tumor-inhibiting exposure. However, the currently available data are limited to preclinical and early safety assessments, making the expansion cohort's patient ORR and duration of response key inflection points for the company's valuation.
Competitive Landscape and Market Potential
The U.S. standard of care for EGFR exon 20 insertion non-small cell lung cancer includes Johnson & Johnson's (JNJ) Rybrevant (amivantamab-vmjw, a dual EGFR/MET-targeting bispecific antibody) in combination with platinum and pemetrexed, which the FDA approved on March 1, 2024, for first-line treatment. In HER2-mutant metastatic non-small cell lung cancer, AstraZeneca (AZN) and Daiichi Sankyo (4568.T)'s Enhertu (fam-trastuzumab deruxtecan-nxki, a HER2-targeting antibody-drug conjugate) received accelerated approval from the FDA on August 11, 2022. Enhertu's global cumulative sales in 2025 were $4.982 billion, demonstrating the commercial scale of HER2-targeted therapies. To enter the established antibody and antibody-drug conjugate market, YH42946 must differentiate itself through oral administration, avoidance of wild-type EGFR, and potential for treating brain metastases.
Regulatory Timelines and Asset Value
The FDA approved the Investigational New Drug (IND) application for the YH42946 Phase 1/2 clinical trial on July 24, 2024. According to ClinicalTrials.gov, the anticipated primary completion date is March 15, 2028, and the overall completion date is July 29, 2028. In 2023, Yuhan Corporation acquired global rights to JIN-A04 from J INTS BIO for a total contract value of 429.8 billion Korean won, with an upfront payment of 2.5 billion Korean won, and the remainder consisting of development, regulatory, and commercial milestone payments. At the time, this translated to a total of $325.8 million, with an upfront payment of approximately $1.9 million, representing a structure that is more heavily weighted towards clinical success than initial cash outlays. If early human data replicate the preclinical selectivity and central nervous system activity, this will enhance the company's negotiating power for subsequent global partnerships and expansion of indications.
YH42946 is conducting a Phase 1/2 trial with 161 patients, targeting both HER2 aberrations and EGFR exon 20 insertion in solid tumors, thereby securing a broader development pathway than a single, rare-mutation asset. In the short term, the 21-day DLT assessment, maximum tolerated dose, pharmacokinetics, and initial ORR will determine the development milestones and the potential for future technology transfer value for Yuhan Corporation, which is valued at $325.8 million. In the medium to long term, the competitive benchmarks are the FDA-approved therapies Rybrevant and Enhertu, with Enhertu's 2025 sales of $4.982 billion setting the clinical and commercial standard for the HER2 market. From an R&D perspective, the key question is whether the selectivity against wild-type EGFR and the activity in brain metastasis models can be confirmed in patients. From an industry perspective, the expansion cohort data, expected before the primary completion date in 2028, will determine the differentiation of this oral TKI.
Source: ClinicalTrials.gov (api_ct)